External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

Key points (machine generated)<ul><li>Roivant Sciences is set to close a $7.25 billion deal with Roche for Telavant, bringing their total value to $12 billion.</li><li>Despite the negative sentiment in the biotech industry, ROIV shares have the potential for over 100% upside with minimal downside, making it an attractive investment opportunity.</li><li>ROIV is likely to return capital to shareholders, benefiting existing holders such as Softbank and Sumitomo.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)Roivant Sciences is set to close a $7.25 billion deal with Roche for Telavant, bringing their total value to $12 billion.Despite the negative sentiment in the biotech industry, ROIV shares have the potential for over 100% upside with minimal downside, making it an attractive investment opportunity.ROIV is likely to return capital to shareholders, benefiting existing holders such as Softbank and Sumitomo.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Roivant Sciences Ltd (ROIV) - Wednesday, Dec 13, 2023

United States

Roivant Sciences Ltd. operates as a healthcare company. The Company offers investigational drugs in development for therapeutic areas such as dermatology, immunology, and respiratory diseases, as well as provides healthcare technologies which help healthcare institutions share and aggregate data. Roivant Sciences provides services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Roivant Sciences Ltd (ROIV US)

Roivant Sciences Ltd (ROIV) - Wednesday, Dec 13, 2023

Roivant Sciences is finalizing a deal with Roche for their company Telavant for $7.25 billion, which would bring their total value to $12, despite...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)